Los Angeles, CA (September 27, 2023) – The Celiac Disease Foundation, the nation’s leading patient advocacy organization for celiac disease, today is proud to announce its newest Board of Directors appointee, Dan Gibbons, who joins the organization this month.
Dan’s desire to join the Celiac Disease Foundation Board was motivated by his personal experience – first enduring undiagnosed celiac disease, and now the everyday challenge of maintaining a strict gluten-free diet. Since his diagnosis in 2010, the Foundation has served as an important resource as Dan has learned to cope with this genetic autoimmune disease, and he looks forward to working with the Foundation to continue to support all of those affected.
“I have witnessed the incredible work the Celiac Disease Foundation has done to raise awareness, secure federal funding, and support critical disease research,” Dan said. “As a Board member, I will be dedicated to supporting the Celiac Disease Foundation as the leading patient advocacy organization committed to accelerating diagnosis, treatments, and ultimately a cure for celiac disease.”
Dan is a Partner at the law firm Davis Polk & Wardwell LLP, practicing in the Capital Markets group in New York. In this role, he advises companies and financial institutions on initial public offerings and other capital raising transactions, securities law compliance, and general corporate matters. Dan received his B.S. in statistics from The George Washington University in 2010 with Phi Beta Kappa honors, and his J.D. from NYU School of Law in 2014. He is admitted to practice law in the State of New York.
Outside of work, Dan is an avid traveler – since being diagnosed with celiac disease, he has visited over 60 countries. Dan currently lives in New York with his wife and their dog.
Biographies of the Celiac Disease Foundation Board of Directors can be found here.
About the Celiac Disease Foundation
The Celiac Disease Foundation, established in 1990, is a leading global patient advocacy organization committed to accelerating diagnosis, treatments, and a cure for celiac disease. Our mission is to improve the health and well-being of the millions of individuals around the world affected by this genetic autoimmune disease through our strategic investments in research, advocacy, and education. Our iCureCeliac® patient registry and extensive patient recruitment services at iRecruitCeliac.org enable us to identify qualified patient candidates and speed their enrollment to advance critical disease research. Our unparalleled advocacy program has led the way to secure federal recognition and first-ever research funding from agencies including the U.S. National Institutes of Health and the Department of Defense. We adhere to the highest scientific and ethical standards as we work each day to promote understanding of celiac disease, empower our patient and provider community, and collaborate with partners and stakeholders to carry our mission forward.